OneSource supports Second Generic Semaglutide approval in Canada- Enables commercialisation for the first two entrants in the World''s second largest Semaglutide market.
ONESOURCE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.1 pts less than Nifty Smallcap 250 and 0.4 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
OneSource Specialty Pharma's partner Orbicular, along with its Canadian front-end partner, received approval from Health Canada for a generic version of Ozempic® (semaglutide injection). This is the second generic semaglutide approval in Canada, making the partners the first generic entrants in this major market. OneSource acted as the manufacturing partner, providing end-to-end manufacturing from its US FDA-approved facility in Bengaluru. Orbicular led the product development and technical program for the complex peptide. The approval follows a recent tentative approval in the United States also supported by OneSource, reinforcing the company's position in complex peptide-based injectable programs. Commercial supply to India has already begun following product launches in March.
The back-to-back approvals in two major regulated markets (Canada and US) strengthen OneSource's credibility as a global CDMO and highlight its manufacturing capabilities for complex peptide-based injectables, which could drive future partnerships and revenue growth.